Keros Therapeutics Inc
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias… Read more
Keros Therapeutics Inc (KROS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.005x
Based on the latest financial reports, Keros Therapeutics Inc (KROS) has a cash flow conversion efficiency ratio of 0.005x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.25 Million) by net assets ($703.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Keros Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Keros Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Keros Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Keros Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ZheJiang ZhongKe Magnetic Co. Ltd. A
SHE:301141
|
N/A |
|
Guangzhou Newlife New Material Co. Ltd. A
SHE:301323
|
N/A |
|
Holding Bursátil Regional S.A.
SN:NUAM
|
N/A |
|
Blue Water Acquisition Corp. III Class A Ordinary Shares
NASDAQ:BLUW
|
-0.001x |
|
Yunnan Shennong Agricultural Industry Group Co Ltd
SHG:605296
|
-0.018x |
|
Ares Commercial Real Estate
NYSE:ACRE
|
0.009x |
|
Huamei Holding
SHE:000607
|
0.029x |
|
Maoye Commercial Co Ltd
SHG:600828
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Keros Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Keros Therapeutics Inc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $571.55 Million | $-160.87 Million | -0.281x | +24.90% |
| 2023-12-31 | $332.21 Million | $-124.51 Million | -0.375x | -48.40% |
| 2022-12-31 | $277.42 Million | $-70.06 Million | -0.253x | +1.18% |
| 2021-12-31 | $243.17 Million | $-62.15 Million | -0.256x | -81.30% |
| 2020-12-31 | $261.72 Million | $-36.89 Million | -0.141x | +95.20% |
| 2019-12-31 | $5.45 Million | $-16.00 Million | -2.935x | -631.71% |
| 2018-12-31 | $12.76 Million | $7.04 Million | 0.552x | -- |